These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 35196631)

  • 1. Dual blockade of MET and VEGFR2 signaling pathways as a potential therapeutic maneuver for peritoneal carcinomatosis in scirrhous gastric cancer.
    Kasai S; Kuwayama N; Motoo Y; Kawashima A; Matsumoto K; Yano S; Matsushima K; Yasumoto K
    Biochem Biophys Res Commun; 2022 Apr; 600():80-86. PubMed ID: 35196631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paracrine activation of MET promotes peritoneal carcinomatosis in scirrhous gastric cancer.
    Zhao L; Yasumoto K; Kawashima A; Nakagawa T; Takeuchi S; Yamada T; Matsumoto K; Yonekura K; Yoshie O; Yano S
    Cancer Sci; 2013 Dec; 104(12):1640-6. PubMed ID: 24118504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The EGFR ligands amphiregulin and heparin-binding egf-like growth factor promote peritoneal carcinomatosis in CXCR4-expressing gastric cancer.
    Yasumoto K; Yamada T; Kawashima A; Wang W; Li Q; Donev IS; Tacheuchi S; Mouri H; Yamashita K; Ohtsubo K; Yano S
    Clin Cancer Res; 2011 Jun; 17(11):3619-30. PubMed ID: 21482691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual targeting c-met and VEGFR2 in osteoblasts suppresses growth and osteolysis of prostate cancer bone metastasis.
    Lee C; Whang YM; Campbell P; Mulcrone PL; Elefteriou F; Cho SW; Park SI
    Cancer Lett; 2018 Feb; 414():205-213. PubMed ID: 29174801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the CXCL12/CXCR4 axis in peritoneal carcinomatosis of gastric cancer.
    Yasumoto K; Koizumi K; Kawashima A; Saitoh Y; Arita Y; Shinohara K; Minami T; Nakayama T; Sakurai H; Takahashi Y; Yoshie O; Saiki I
    Cancer Res; 2006 Feb; 66(4):2181-7. PubMed ID: 16489019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of dual targeting of tumor cells and stroma in human glioblastoma xenografts with a tyrosine kinase inhibitor against c-MET and VEGFR2.
    Navis AC; Bourgonje A; Wesseling P; Wright A; Hendriks W; Verrijp K; van der Laak JA; Heerschap A; Leenders WP
    PLoS One; 2013; 8(3):e58262. PubMed ID: 23484006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET.
    Xiang Q; Chen W; Ren M; Wang J; Zhang H; Deng DY; Zhang L; Shang C; Chen Y
    Clin Cancer Res; 2014 Jun; 20(11):2959-70. PubMed ID: 24700742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.
    Yakes FM; Chen J; Tan J; Yamaguchi K; Shi Y; Yu P; Qian F; Chu F; Bentzien F; Cancilla B; Orf J; You A; Laird AD; Engst S; Lee L; Lesch J; Chou YC; Joly AH
    Mol Cancer Ther; 2011 Dec; 10(12):2298-308. PubMed ID: 21926191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer.
    Varkaris A; Corn PG; Parikh NU; Efstathiou E; Song JH; Lee YC; Aparicio A; Hoang AG; Gaur S; Thorpe L; Maity SN; Bar Eli M; Czerniak BA; Shao Y; Alauddin M; Lin SH; Logothetis CJ; Gallick GE
    Clin Cancer Res; 2016 Jan; 22(1):107-21. PubMed ID: 26272062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel inhibitor of c-Met and VEGF receptor tyrosine kinases with a broad spectrum of in vivo antitumor activities.
    Awazu Y; Nakamura K; Mizutani A; Kakoi Y; Iwata H; Yamasaki S; Miyamoto N; Imamura S; Miki H; Hori A
    Mol Cancer Ther; 2013 Jun; 12(6):913-24. PubMed ID: 23548264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.
    Bentzien F; Zuzow M; Heald N; Gibson A; Shi Y; Goon L; Yu P; Engst S; Zhang W; Huang D; Zhao L; Vysotskaia V; Chu F; Bautista R; Cancilla B; Lamb P; Joly AH; Yakes FM
    Thyroid; 2013 Dec; 23(12):1569-77. PubMed ID: 23705946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted dual inhibition of c-Met/VEGFR2 signalling by foretinib improves antitumour effects of nanoparticle paclitaxel in gastric cancer models.
    Grojean M; Schwarz MA; Schwarz JR; Hassan S; von Holzen U; Zhang C; Schwarz RE; Awasthi N
    J Cell Mol Med; 2021 Jun; 25(11):4950-4961. PubMed ID: 33939252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model.
    Song EK; Tai WM; Messersmith WA; Bagby S; Purkey A; Quackenbush KS; Pitts TM; Wang G; Blatchford P; Yahn R; Kaplan J; Tan AC; Atreya CE; Eckhardt G; Kelley RK; Venook A; Kwak EL; Ryan D; Arcaroli JJ
    Int J Cancer; 2015 Apr; 136(8):1967-75. PubMed ID: 25242168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway-induced resistance to vascular endothelial growth factor receptor inhibitor.
    Nakagawa T; Matsushima T; Kawano S; Nakazawa Y; Kato Y; Adachi Y; Abe T; Semba T; Yokoi A; Matsui J; Tsuruoka A; Funahashi Y
    Cancer Sci; 2014 Jun; 105(6):723-30. PubMed ID: 24689876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenoviral-mediated gene transduction of the hepatocyte growth factor (HGF) antagonist, NK4, suppresses peritoneal metastases of gastric cancer in nude mice.
    Ueda K; Iwahashi M; Matsuura I; Nakamori M; Nakamura M; Ojima T; Naka T; Ishida K; Matsumoto K; Nakamura T; Yamaue H
    Eur J Cancer; 2004 Sep; 40(14):2135-42. PubMed ID: 15341989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer.
    Toiyama Y; Yasuda H; Saigusa S; Matushita K; Fujikawa H; Tanaka K; Mohri Y; Inoue Y; Goel A; Kusunoki M
    Int J Cancer; 2012 Jun; 130(12):2912-21. PubMed ID: 21796631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autocrine VEGF signaling promotes cell proliferation through a PLC-dependent pathway and modulates Apatinib treatment efficacy in gastric cancer.
    Lin Y; Zhai E; Liao B; Xu L; Zhang X; Peng S; He Y; Cai S; Zeng Z; Chen M
    Oncotarget; 2017 Feb; 8(7):11990-12002. PubMed ID: 28061477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment.
    Kwon Y; Smith BD; Zhou Y; Kaufman MD; Godwin AK
    Oncogene; 2015 Jan; 34(2):144-53. PubMed ID: 24362531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, for Scirrhous gastric cancer.
    Nakamura K; Yashiro M; Matsuoka T; Tendo M; Shimizu T; Miwa A; Hirakawa K
    Gastroenterology; 2006 Nov; 131(5):1530-41. PubMed ID: 17101326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MET Suppresses Epithelial VEGFR2 via Intracrine VEGF-induced Endoplasmic Reticulum-associated Degradation.
    Chen TT; Filvaroff E; Peng J; Marsters S; Jubb A; Koeppen H; Merchant M; Ashkenazi A
    EBioMedicine; 2015 May; 2(5):406-20. PubMed ID: 26137585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.